SINT

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

SINTX

Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

Third-quarter

revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance

Revenue milestone also enables Company to call Class B warrants

SALT

LAKE CITY, Utah – October 1, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary, unaudited revenue of $2.2 million* for the third quarter ended September 30, 2026. The result exceeds the high end of the Company’s previously announced guidance of $0.9 million to $1.1 million, reflecting stronger-than-expected industrial ceramics sales, and is expected to result in narrower losses than previous quarters.

Sales of industrial parts to aerospace subsidiaries of Fortune 500 companies accounted for the majority of third-quarter revenue. During the quarter, SINTX began shipments against the more than $3.2 million in contract manufacturing purchase orders announced in June, converting a portion of those orders into recognized revenue. The Company reiterates its fourth-quarter revenue guidance range offered during its last quarterly earnings call.

“We are pleased by the results of our efforts to improve manufacturing and operational efficiency in the third quarter,” said Eric Olson, Chairman and CEO of SINTX. “In addition to the significantly narrowed losses we expect to see as a result of these sales and nearly doubling the high end of the guidance we provided in August, our 2026 third-quarter revenue represents growth of roughly 380% from the second quarter, and over ten times the revenue from the prior year quarter.”

During 2026, SINTX has expanded the commercial infrastructure supporting its silicon nitride orthopedic portfolio, including its FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System. SINTX continues to develop its silicon nitride SiNERGY™ technology platform across biocomposite and 3D printing capabilities, as well as its antimicrobial textiles as part of the overall platform for orthopedic, spine, craniofacial, dental, suture and wound-management applications.

Mr. Olson continued, “This quarter demonstrates our ability to turn industrial customer orders into revenue at scale through our U.S. manufacturing operations. Our focus now is on reliable delivery, repeat business and disciplined manufacturing costs. We see this execution as an important foundation for SINTX as we continue our transition towards a more diversified commercial-stage advanced materials company.”

Concurrent with issuing this press release on Form 8-K, the Company also intends to deliver a Call Notice to the holders of Class B Warrants to purchase an aggregate of approximately 1.88 million shares of the Company’s Common Stock. Roughly $2.1 million of the third-quarter revenue was derived from product sales, surpassing the Call Right trigger of at least $2.0 million in product revenue during a fiscal quarter. Per the terms of the Warrant, the per share exercise price shall be the closing price of the Company’s Common Stock at the close of the trading day immediately preceding the date of the Call Notice; if fully exercised under the terms of the Warrant, cash proceeds could provide up to $4.0 million in additional capital, while any Warrants or portion of Warrants that the Holders fail to exercise in a timely manner will automatically expire. Exercise proceeds are not assured.

*This amount represents preliminary recognized revenue for the quarter, while the Company is completing its quarter-end financial close and review procedures. The preliminary revenue figure is based on information currently available to management, is unaudited, and remains subject to adjustment. SINTX expects to provide complete third-quarter financial results in its forthcoming quarterly reporting. Final reported revenue could differ materially.

About SINTX Technologies, Inc.

Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System for reconstructive surgery.

Forward-Looking

Statements

This press release contains forward-looking statements within the meaning of the Private Securit

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

SINTX

Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

SALT

LAKE CITY, Utah – August 11, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System, expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued to broaden the application of its proprietary silicon nitride technology platform across multiple healthcare and industrial markets.

These accomplishments reflect the Company’s strategic transition from technology development toward commercial execution while continuing to build a diversified portfolio of growth opportunities designed to create long-term shareholder value.

“Our strategy has always extended well beyond the introduction of a single medical device,” said Eric K. Olson, Chairman, President and Chief Executive Officer of SINTX Technologies. “During the first half of 2026, we continued building the commercial infrastructure, manufacturing capabilities, and strategic relationships necessary to support our growth strategy, while raising additional capital and implementing measures designed to preserve liquidity and improve operating efficiency. We believe silicon nitride represents a differentiated technology platform with the potential to address multiple high-value healthcare and industrial markets, and we remain focused on translating these investments into increasing commercial adoption, expanding revenue opportunities and potential long-term value creation.”

Commercial Execution Accelerates

Following FDA 510(k) clearance in October 2025, SINTX initiated a Limited Use Release (“LUR”) of its SiNAPTIC® Foot & Ankle Osteotomy Wedge System during the first half of 2026. The LUR is intended to support surgeon training, clinical adoption and commercialization ahead of broader market expansion.

To support this commercialization effort, the Company established its initial network of twelve independent orthopedic distributors specializing in foot and ankle surgery. As surgeon adoption continues to expand, SINTX expects this commercial infrastructure to support broader market penetration throughout the United States.

The Company believes SiNAPTIC’s proprietary silicon nitride biomaterial offers meaningful clinical differentiation through its demonstrated bone affinity and inherent resistance to bacterial adhesion, characteristics that position the platform for potential expansion into additional orthopedic applications.

Multiple Revenue Opportunities Continue to Expand

While advancing commercialization of its medical technologies, SINTX continued to expand its established industrial ceramics business.

During the first half of 2026, the Company received approximately $3.2 million in new industrial purchase orders from multiple contract manufacturing customers for the production of advanced ceramic components serving demanding, high-performance applications. Initial shipments have commenced, and the Company currently expects to recognize revenue associated with these purchase orders beginning in the third quarter of 2026, subject to delivery schedules, customer acceptance and applicable revenue-recognition requirements.

Management believes the industrial business provides an important commercial foundation that supports continued investment in higher-growth medical technologies while diversifying the Company’s revenue base.

Revenue Outlook for the Second Half of 2026

Reflecting increased commercial activity and the commencement of production and shipments associated with previously announced customer purchase orders, SINTX currently expects total revenue to be approximately $900,000 to $1.1 million for the third quarter of 2026 and approximately $1.0 million to $1.3 million for the fourth quarter of 2026.

This outlook is based on current production schedules, customer requirements and management’s expectations regarding manufacturing execution, shipments and the timing of revenue recognition. The Company’s outlook is subject to significant uncertainty, including potential changes in customer schedules, material availability, manufacturing yield and capacity, quality release, shipment timing, customer acceptance and product mix. Accordingly, actual results could differ materially from these expectations.

The Company continues to view the approximately $3.2 million of previously announced industrial purchase orders as an important source of commercial visibility, while recognizing that purchase

false 0001269026

0001269026

2025-11-13 2025-11-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 13, 2025

SINTX

Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-33624

84-1375299

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS

Employer

Identification No.)

1885 West 2100 South

Salt Lake City, UT

84119

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (801) 839-3500

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading Symbol(s):

Name of each exchange on which registered:

Common Stock, par value $0.01 per share

SINT

The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2025, SINTX Technologies, Inc. (the “Company”) issued a press release announcing financial results for its quarter ended September 30, 2025. The full text of the press release, which includes information regarding the Company’s use of a non-GAAP financial measure, is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD. Disclosure.

The information set forth under Item 2.02 is incorporated by reference as if fully set forth herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release, dated November 13, 2025

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SINTX

TECHNOLOGIES, INC.

Date: November 13, 2025 /s/ Eric Olson

Eric Olson

President and Chief Executive Officer